Agreed that BioNTech should share the credit, but it's important to note that scaling up production of a new type of vaccine with a whole host of unknowns associated with it is not a trivial matter. Nor is running a largish clinical trial at breakneck speed. Pfizer deserves credit along with BioNTech.